Pfizer Stock Slips After Report on Vaccine Timing Probe
Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.
Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...
Additionally, US exchanges like the New York Stock Exchange and Nasdaq are among the most liquid in the world, making it easy for investors to buy and sell shares efficiently.
Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.
We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other undervalued S&P 500 ...
Community Bank N.A. cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 26.5% in the fourth quarter, according to its ...
Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...
With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...
Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...
Wednesday brought with it yet another positive development concerning the COVID omicron strain, but while it wasn't enough to drive a third day of aggressive gains, it was enough to keep many ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback